pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.17238/PmJ1609-1175.2019.1.5-12pmj-295Research ArticleПЕРЕДОВЫЕ СТАТЬИEDITORIALSДискуссионные вопросы терапии хронической обструктивной болезни легких (материалы совета экспертов ДФО от 13.06.2018 г., Владивосток)Argumentative issues of chronic obstructive pulmonary disease (materials of panel of experts, Far Eastern Federal District from 06/13/2018, Vladivostok)НевзороваВ. А.NevzorovaV. A.noemail@neicon.ruАвдеевС. Н.AvdeevS. N.noemail@neicon.ruКондрашоваН. М.KondrashovaN. M.noemail@neicon.ruШуматовВ. Б.ShumatovV. B.noemail@neicon.ruКуделяЛ. М.KudelyaL. M.noemail@neicon.ruСухановаГ. И.SukhanovaG. I.noemail@neicon.ruКиняйкинМ. Ф.KinyaykinM. F.noemail@neicon.ruНаумоваИ. В.NaumovaI. V.noemail@neicon.ruКудрявцеваВ. А.KudryavtsevaV. A.noemail@neicon.ruХижнякЮ. Ю.KhizhnyakYu. Yu.noemail@neicon.ruМусатовИ. Б.MusatovI. B.noemail@neicon.ruТихоокеанский государственный медицинский университетРоссияPacific State Medical UniversityRussian FederationПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian FederationГосударственная Новосибирская областная клиническая больницаРоссияState Novosibirsk Regional Clinical HospitalRussian FederationВладивостокский клинико-диагностический центрРоссияVladivostok Clinical and Diagnostic CenterRussian FederationГородская поликлиника № 4 Южно-СахалинскаРоссияYuzhno-Sakhalinsk City Outpatient Clinic No. 4Russian FederationСпасская городская поликлиникаРоссияSpassk City Outpatient ClinicRussian Federation20192803201901512Copyright © Невзорова В.А., Авдеев С.Н., Кондрашова Н.М., Шуматов В.Б., Куделя Л.М., Суханова Г.И., Киняйкин М.Ф., Наумова И.В., Кудрявцева В.А., Хижняк Ю.Ю., Мусатов И.Б., 20192019Невзорова В.А., Авдеев С.Н., Кондрашова Н.М., Шуматов В.Б., Куделя Л.М., Суханова Г.И., Киняйкин М.Ф., Наумова И.В., Кудрявцева В.А., Хижняк Ю.Ю., Мусатов И.Б.Nevzorova V.A., Avdeev S.N., Kondrashova N.M., Shumatov V.B., Kudelya L.M., Sukhanova G.I., Kinyaykin M.F., Naumova I.V., Kudryavtseva V.A., Khizhnyak Y.Y., Musatov I.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/295

В статье отражены дискуссионные вопросы лечения хронической обструктивной болезни легких (ХОБЛ), представляющей глобальную проблему современной медицины. По данным ВОЗ, ХОБЛ - третья лидирующая причина смерти в мире. Ежегодно от этого заболевания умирает около 2,8 млн человек, и за последние двадцать лет данная статистика не изменилась. В развитых странах наибольшие затраты для систем здравоохранения в лечении заболеваний дыхательных путей связаны с обострениями ХОБЛ, которые негативно влияют на течение этого заболевания, вызывая необратимое прогрессирующее снижение функции легких, ухудшение качества жизни, увеличивают частоту повторных госпитализаций и смертность. Таким образом, предотвращение обострений ХОБЛ имеет социальную и экономическую значимость и должно стать первостепенной задачей при лечении данного заболевания.

The article represents argumentative issues of Chronic Obstructive Pulmonary Disease (COPD) treatment which is a global problem of modern medicine. According to WHO data COPD is the third leading cause of death worldwide, annually about 2.8 million people die because of this disease, and over 20 years this statistics never changed. In developed countries the highest costs for health systems in the treatment of respiratory diseases are associated with COPD which affect the course of this disease causing an irreversible progressive decline in lung function, deteriorating quality of life, increasing the frequency of readmissions and mortality. Thus, the prevention of exacerbations of COPD is of social and economic importance and should be a priority in the treatment of this disease.

обострение хронической обструктивной болезни легкихпротивовоспалительная терапияэкстрамелкодисперсные ингаляционные глюкокортикостероидыexacerbations of chronic obstructive pulmonary diseaseanti-inflammatory therapyextra-micronisedinhaled glucocorticosteroidsReferencesВОЗ. Информационный листок № 297. 2018. URL: http:// www.who.int/mediacentre/factsheets/fs297/en/ (дата доступа: 03.11.2018).ВОЗ. Информационный листок № 297. 2018. URL: http:// www.who.int/mediacentre/factsheets/fs297/en/ (дата доступа: 03.11.2018).ВОЗ. Информационный листок № 310. 2018 URL: http:// www.who.int/mediacentre/factsheets/fs310/en/ (дата доступа: 03.11.2018).ВОЗ. Информационный листок № 310. 2018 URL: http:// www.who.int/mediacentre/factsheets/fs310/en/ (дата доступа: 03.11.2018).Крысанов И.С. Анализ стоимости хронической обструктивной болезни легких в Российской Федерации // Качественная клиническая практика. 2014. № 2. С. 51-56.Крысанов И.С. Анализ стоимости хронической обструктивной болезни легких в Российской Федерации // Качественная клиническая практика. 2014. № 2. С. 51-56.Росстат. Демографический ежегодник. URL: http://www. gks.ru/free_doc/new_site/population/demo/smert.htm (дата обращения: 03.12.2018).Росстат. Демографический ежегодник. URL: http://www. gks.ru/free_doc/new_site/population/demo/smert.htm (дата обращения: 03.12.2018).Хроническая обструктивная болезнь легких: федеральные клинические рекомендации. М.: Российское респираторное общество, 2018. URL: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ (дата обращения: 03.12.2018).Хроническая обструктивная болезнь легких: федеральные клинические рекомендации. М.: Российское респираторное общество, 2018. URL: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ (дата обращения: 03.12.2018).Andersson F., Borg S., Jansson S.A. [et al.]. The costs of exacerbations in chronic obstructive pulmonary disease // Respiratory Medicine. 2002. Vol. 96. P. 700-708.Andersson F., Borg S., Jansson S.A. [et al.]. The costs of exacerbations in chronic obstructive pulmonary disease // Respiratory Medicine. 2002. Vol. 96. P. 700-708.Braido F., Scichilone N., Lavorini F. [et al.]. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) // Asthma Research and Practice. 2016. No. 2. P. 12.Braido F., Scichilone N., Lavorini F. [et al.]. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) // Asthma Research and Practice. 2016. No. 2. P. 12.Brusselle G., Price D., Gruffydd-Jones K. [et al.]. The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK // International Journal of COPD. 2015. Vol. 10. P. 2207-2217.Brusselle G., Price D., Gruffydd-Jones K. [et al.]. The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK // International Journal of COPD. 2015. Vol. 10. P. 2207-2217.Dransfield M.T. Bourbeau J., Jones P.W. [et al.]. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate double-blind, parallel-group, randomised controlled trials // Lancet Respir. Med. 2013. Vol. 1, No. 3. P. 210-223.Dransfield M.T. Bourbeau J., Jones P.W. [et al.]. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate double-blind, parallel-group, randomised controlled trials // Lancet Respir. Med. 2013. Vol. 1, No. 3. P. 210-223.EMA: PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease. URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news_and_events/news/2016/03/news_detail_002491. jsp&mid=WC0b01ac058004d5c1 (date of access: 11.11.2018).EMA: PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease. URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news_and_events/news/2016/03/news_detail_002491. jsp&mid=WC0b01ac058004d5c1 (date of access: 11.11.2018).Ferguson G.T., Rabe K.F., Martinez F.J. [et al.]. Triple combination of budesonide/glycopyrrolate /formoterol fumarate using co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A doubleblind, parallel-group, randomised controlled trial // Lancet Respir. Med. 2018. URL: https://www.thelancet.com/journals/ lanres/article/PIIS2213-2600(18)30327-8/fulltext (date of access: 03.11.2018).Ferguson G.T., Rabe K.F., Martinez F.J. [et al.]. Triple combination of budesonide/glycopyrrolate /formoterol fumarate using co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A doubleblind, parallel-group, randomised controlled trial // Lancet Respir. Med. 2018. URL: https://www.thelancet.com/journals/ lanres/article/PIIS2213-2600(18)30327-8/fulltext (date of access: 03.11.2018).Festic E., Bansal V., Gupta E. [et al.]. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients: Systematic review and meta-analysis // COPD. 2016. Vol. 13, No. 3. P. 312-326.Festic E., Bansal V., Gupta E. [et al.]. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients: Systematic review and meta-analysis // COPD. 2016. Vol. 13, No. 3. P. 312-326.Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. URL: https://goldcopd.org/wp-content/ uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS. pdf (date of access: 03.11.2018).Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. URL: https://goldcopd.org/wp-content/ uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS. pdf (date of access: 03.11.2018).GOLD 2017. URL: https://goldcopd.org/wp-content/up-loads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf (date of access: 11.11.2018).GOLD 2017. URL: https://goldcopd.org/wp-content/up-loads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf (date of access: 11.11.2018).Hastie A.T., Martinez F.J., Curtis J.L. [et al.]. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: An analysis of the SPIROMICS cohort // Lancet Respir. Med. 2017. Vol. 5, No. 12. P. 956-967.Hastie A.T., Martinez F.J., Curtis J.L. [et al.]. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: An analysis of the SPIROMICS cohort // Lancet Respir. Med. 2017. Vol. 5, No. 12. P. 956-967.Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease // Cochrane Database of Systematic Reviews. 2014. 3. CD010115. URL: https://doi.org/10.1002/14651858.CD010115.pub2 (date of access: 11.11.2018).Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease // Cochrane Database of Systematic Reviews. 2014. 3. CD010115. URL: https://doi.org/10.1002/14651858.CD010115.pub2 (date of access: 11.11.2018).King P.T. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer // Clin. Transl. Med. 2015. Vol. 4, No. 1. P. 68. doi: 10.1186/s40169-015-0068-z.King P.T. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer // Clin. Transl. Med. 2015. Vol. 4, No. 1. P. 68. doi: 10.1186/s40169-015-0068-z.Lipson D.A, Barnhart F., Brealey N. [et al.]. Once-daily singleinhaler triple versus dual therapy in patients with COPD // N. Engl. J. Med. 2018. Vol. 378, No. 18. Р. 1671-1680.Lipson D.A, Barnhart F., Brealey N. [et al.]. Once-daily singleinhaler triple versus dual therapy in patients with COPD // N. Engl. J. Med. 2018. Vol. 378, No. 18. Р. 1671-1680.Lipworth B., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD // Int. J. Chron. Obstruct. Pulmon. Dis. 2018. Vol. 13. P. 3003-3009.Lipworth B., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD // Int. J. Chron. Obstruct. Pulmon. Dis. 2018. Vol. 13. P. 3003-3009.Papi A., Vestbo J., Fabbri L. [et al.]. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial // Lancet. 2018. Vol. 391, No. 10125. P. 1076-1084.Papi A., Vestbo J., Fabbri L. [et al.]. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial // Lancet. 2018. Vol. 391, No. 10125. P. 1076-1084.Polosukhin V.V., Richmond B.W., Du R.H. [et al.]. Secretory IgA deficiency in individual small airways is associated with persistent inflammation and remodeling // Am. J. Respir. Crit. Care Med. 2017. Vol. 195, No. 8. P. 1010-1021.Polosukhin V.V., Richmond B.W., Du R.H. [et al.]. Secretory IgA deficiency in individual small airways is associated with persistent inflammation and remodeling // Am. J. Respir. Crit. Care Med. 2017. Vol. 195, No. 8. P. 1010-1021.Price D., West D., Brusselle G. [et al.]. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns // International Journal of COPD. 2014. No. 9. P. 889-905.Price D., West D., Brusselle G. [et al.]. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns // International Journal of COPD. 2014. No. 9. P. 889-905.Siddiqui S.H., Pavord I.D., Barnes N.C. [et al.]. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids // Int. J. Chron. Obstruct. Pulmon. Dis. 2018. Vol. 13. P. 3669-3676.Siddiqui S.H., Pavord I.D., Barnes N.C. [et al.]. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids // Int. J. Chron. Obstruct. Pulmon. Dis. 2018. Vol. 13. P. 3669-3676.Singh D., Nicolini G., Bindi E. [et al.]. Comparison of extra fine beclomethasone dipropionate/formoterol fumarate versus other double combinations on reduction of moderate/severe exacerbations // BMC Pulm. Med. 2014. doi: 10.1186/1471-2466-14-43 (date of access: 11.11.2018).Singh D., Nicolini G., Bindi E. [et al.]. Comparison of extra fine beclomethasone dipropionate/formoterol fumarate versus other double combinations on reduction of moderate/severe exacerbations // BMC Pulm. Med. 2014. doi: 10.1186/1471-2466-14-43 (date of access: 11.11.2018).Singh D., Papi A., Corradi M. [et al.]. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting ß2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial // Lancet. 2016. Vol. 388. P. 963-973.Singh D., Papi A., Corradi M. [et al.]. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting ß2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial // Lancet. 2016. Vol. 388. P. 963-973.Sonnappa S., Martin R., Israel E. [et al.]. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids // PLoS One. 2017. URL: https://doi.org/10.1371/journal.pone.0178112 (date of access: 11.11.2018).Sonnappa S., Martin R., Israel E. [et al.]. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids // PLoS One. 2017. URL: https://doi.org/10.1371/journal.pone.0178112 (date of access: 11.11.2018).Stänescu D., Sanna A., Veriter C. [et al.]. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils // Thorax. 1996. Vol. 51, No. 3. P. 267-271.Stänescu D., Sanna A., Veriter C. [et al.]. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils // Thorax. 1996. Vol. 51, No. 3. P. 267-271.Vedel-Krogh S., Nielsen S.F., Lange P. [et al.]. Blood eosinophils and COPD exacerbations // Am. J. Respir. Crit. Care Med. 2016. Vol. 193, No. 9. P. 965-974.Vedel-Krogh S., Nielsen S.F., Lange P. [et al.]. Blood eosinophils and COPD exacerbations // Am. J. Respir. Crit. Care Med. 2016. Vol. 193, No. 9. P. 965-974.Vestbo J., Papi A., Corradi M. [et al.]. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A doubleblind, parallel group, randomised controlled trial // Lancet. 2017. Vol. 389. P. 1919-1929.Vestbo J., Papi A., Corradi M. [et al.]. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A doubleblind, parallel group, randomised controlled trial // Lancet. 2017. Vol. 389. P. 1919-1929.WHO. URL: http://www.who.int/en/news-room/fact-sheets/ detail/chronic-obstructive-pulmonary-disease-(copd), https:// www.lung.org/assets/documents/research/copd-trend-report. pdf (date of access: 03.11.2018).WHO. URL: http://www.who.int/en/news-room/fact-sheets/ detail/chronic-obstructive-pulmonary-disease-(copd), https:// www.lung.org/assets/documents/research/copd-trend-report. pdf (date of access: 03.11.2018).

The authors declare that there are no conflicts of interest present.